Lower GI Series Market Research Report By Procedure Type (Barium Enema, Colonoscopy, CT Colonography, Fluoroscopy), By Application (Diagnostic Imaging, Routine Screening, Disease Monitoring, Therapeutic Intervention), By End User (Hospitals, Diagnostic Laboratories, Outpatient Clinics, Research Institutions), By Product Type (Contrast Media, Imaging Equipment, Consumables, Accessories) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Lower GI Series Market Overview

As per MRFR analysis, the Lower GI Series Market Size was estimated at 1.75 (USD Billion) in 2023.The Lower GI Series Market Industry is expected to grow from 1.82(USD Billion) in 2024 to 2.8 (USD Billion) by 2035. The Lower GI Series Market CAGR (growth rate) is expected to be around 3.98% during the forecast period (2025 - 2035).

Key Lower GI Series Market Trends Highlighted

The Global Lower GI Series Market is witnessing notable market trends driven by an increase in gastrointestinal disorders and a rising awareness of preventive healthcare. Advancements in imaging technologies, such as high-resolution fluoroscopy and digital radiography, are enhancing the effectiveness and accuracy of lower GI series procedures. The shift toward more patient-centered care also plays a significant role, as individuals are more informed about their health options and advocate for diagnostic tests that provide timely insights into their gastrointestinal health.  Additionally, the growing geriatric population worldwide is contributing to higher demand for lower GI series imaging, as older adults are more prone to digestive issues.

Opportunities within this market include the enhancement of outreach programs aimed at educating healthcare providers and patients about the benefits of early diagnosis through lower GI imaging. Fostering partnerships between imaging centers and healthcare networks may further strengthen market growth, encouraging wider access to these diagnostic services.  In recent times, there has been an increased emphasis on minimally invasive diagnostic options, pushing healthcare facilities to adopt lower GI series as a standard procedure in conjunction with other diagnostic evaluations. Moreover, legislative initiatives aimed at improving access to preventative screenings and diagnostic imaging services can favorably impact market dynamics.

With a continuous focus on technological innovation and increasing healthcare expenditure globally, the lower GI series continues to evolve, presenting significant growth opportunities in various regions.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Lower GI Series Market Drivers

Rising Incidence of Gastrointestinal Disorders

The rising incidence of gastrointestinal problems is a major factor driving the global lower GI series market industry. The World Health Organization (WHO) estimates that gastrointestinal disorders impact almost one in five people worldwide, with ailments including irritable bowel syndrome and inflammatory bowel disease experiencing a significant increase. Specifically, diseases such as colorectal cancer have been increasing; projections suggest that more than 1.9 million new instances of colorectal cancer were recorded in 2020 alone.

Healthcare systems are being compelled by this concerning trend to implement sophisticated diagnostic instruments, such as Lower GI series. The demand for these treatments is anticipated to rise as a result of organizations such as the American Cancer Society promoting early screening. The global lower gastrointestinal series market is expected to expand significantly as preventative healthcare becomes more and more important. This is in line with the growing demand for efficient diagnostic techniques to treat these conditions.

the Advancements in Medical Imaging Technologies

Technological advancements in medical imaging, particularly in lower gastrointestinal diagnostics, are a significant driver for the Global Lower GI Series Market Industry. Innovations such as high-definition imaging and digital radiography have enhanced the performance of gastrointestinal imaging procedures, allowing for more accurate and faster diagnoses. A report from the Radiological Society of North America suggests that newer imaging technologies can capture up to 50% more detail compared to traditional techniques.

These advancements are attracting healthcare providers towards adopting lower GI series, as they can offer enhanced patient outcomes and improved diagnostic accuracy. Consequently, with support from various technologic entities and associations focusing on maintaining high standards in imaging, the demand for these series is expected to grow significantly.

Increasing Awareness and Preventive Healthcare Initiatives

The growing emphasis on preventive healthcare and public awareness campaigns about gastrointestinal health are crucial market drivers for the Global Lower GI Series Market Industry. Governments and health organizations are increasingly promoting screening programs for early detection of gastrointestinal diseases. For instance, the Centers for Disease Control and Prevention (CDC) reported a significant increase in colorectal cancer screening rates among adults aged 50 to 75 years, from 52% in 2011 to nearly 68% in 2018.

Such initiatives are pivotal as they reinforce the importance of early detection and timely interventions. By raising public awareness and partnering with health professionals, these campaigns are expected to increase the demand for lower GI series, driving market growth in the coming years.

Lower GI Series Market Segment Insights

Lower GI Series Market Procedure Type Insights  

The Global Lower GI Series Market is characterized by a diverse range of procedure types, each offering unique capabilities in diagnosing gastrointestinal conditions. The overall market in 2024 is valued at 1.82 USD Billion and is expected to grow significantly by 2035. Within this growth, the segmentation reveals varying contributions from different procedures. Barium Enema is a notable procedure valued at 0.45 USD Billion in 2024, reflecting its importance in visualizing and diagnosing abnormalities in the colon, which is crucial for identifying issues like tumors or blockages.

The procedure is projected to rise to 0.7 USD Billion by 2035, indicating a steady growth trend. Colonoscopy plays a significant role in this market, with a valuation of 0.7 USD Billion expected in 2024 and projected to reach 1.1 USD Billion by 2035. This procedure, known for its comprehensive examination of the colon, dominates the market due to its effectiveness in screening for colorectal cancer and other disorders, making it a preferred choice among healthcare providers. CT Colonography, valued at 0.35 USD Billion in 2024, is anticipated to grow to 0.55 USD Billion by 2035.

This less invasive imaging method provides valuable insights and is gaining traction due to its ability to offer high-resolution images of the colon. In contrast, Fluoroscopy, with a valuation of 0.32 USD Billion in 2024, is also significant, albeit smaller in the market share, growing to 0.45 USD Billion by 2035. This imaging technique permits the observation of the gastrointestinal tract in real-time, which is valuable for assessing functional aspects of the colon. The combination of these procedure types showcases the Global Lower GI Series Market's versatility, with Colonoscopy holding the majority share, primarily attributed to its critical role in preventive healthcare.

The continuous advancements in medical technology, better patient acceptance, and increasing awareness of gastrointestinal health are propelling the growth of these procedures, making the Global Lower GI Series Market an essential component of modern medical diagnostics.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Lower GI Series Market Application Insights  

The Global Lower GI Series Market revenue is poised for notable growth, projecting a substantial valuation of 1.82 USD Billion by 2024. This market encompasses various applications critical to gastrointestinal health, which include Diagnostic Imaging, Routine Screening, Disease Monitoring, and Therapeutic Intervention. Diagnostic Imaging plays a vital role as it enhances visualization of lower gastrointestinal disorders, aiding in accurate diagnoses. Routine Screening is essential for early detection of potential health issues, significantly impacting patient outcomes, while Disease Monitoring is crucial for tracking the progression of conditions over time.

Therapeutic Intervention addresses active diseases, offering treatments based on the assessments made through other applications. Current trends highlight increasing awareness of gastrointestinal health alongside rising healthcare expenditures, all contributing to the market's expansion. However, challenges such as regulatory hurdles and the necessity for skilled professionals remain pertinent. Opportunities lie in technological advancements and the growing preference for non-invasive procedures in the industry, further fueling the Global Lower GI Series Market growth toward its future projections. As the market evolves, these applications will continue to transform patient care in the gastrointestinal sector.

Lower GI Series Market End User Insights  

The Global Lower GI Series Market is poised to experience steady growth in the coming years, with significant contributions from various End User categories. In 2024, the overall market is valued at 1.82 USD Billion, reflecting a growing demand across healthcare sectors. The market encompasses multiple End Users such as Hospitals, Diagnostic Laboratories, Outpatient Clinics, and Research Institutions, each playing a pivotal role in the delivery of lower gastrointestinal diagnostic services. Hospitals are particularly important as they provide comprehensive care, housing advanced diagnostic technologies.

Diagnostic Laboratories serve as critical hubs for accurate and timely test results, significantly impacting patient outcomes. Outpatient Clinics continue to gain traction due to the rising preference for minimally invasive procedures, providing accessible diagnostic services to patients. Furthermore, Research Institutions contribute to the market by enabling advancements through innovative techniques and studies. Together, these End Users collectively drive the demand for the Global Lower GI Series Market, highlighting the diverse applications and critical need for effective gastrointestinal health management globally.

Market growth is fueled by an aging population, an increasing prevalence of gastrointestinal disorders, and a growing focus on preventive healthcare. However, challenges such as regulatory hurdles and the need for skilled professionals pose significant considerations for continued development in this sector.

Lower GI Series Market Product Type Insights  

The Global Lower GI Series Market is a vital segment in the healthcare industry, with a valuation of 1.82 billion USD in 2024 and expected growth to 2.8 billion USD by 2035. Within this market, the segmentation by Product Type encompasses Contrast Media, Imaging Equipment, Consumables, and Accessories, each playing a crucial role in diagnostics and therapeutic procedures. Contrast Media is essential for enhancing the visibility of the gastrointestinal tract during imaging processes, thus significantly impacting diagnostic accuracy. Imaging Equipment, comprising x-rays and various imaging technologies, presents significant advancements that improve patient outcomes through clearer, more detailed visuals.

Consumables, such as syringes and other disposable items, are indispensable for maintaining hygiene and efficiency in procedures. Accessories, while often overlooked, are crucial for the operational efficiency of imaging equipment supporting various healthcare applications. As the market continues to evolve, it presents considerable opportunities for innovation and expansion, addressing critical healthcare needs globally.

Lower GI Series Market Regional Insights  

The Global Lower GI Series Market exhibits notable growth across various regional domains, with North America holding a majority share, valued at 0.82 USD Billion in 2024 and expected to reach 1.2 USD Billion by 2035. This region's significant investment in healthcare infrastructure and advanced medical technologies contributes to its dominant market position. Europe follows with a valuation of 0.5 USD Billion in 2024, projected to increase to 0.75 USD Billion in 2035, driven by rising awareness and advancements in diagnostic procedures. APAC, with an initial valuation of 0.3 USD Billion in 2024, reflects a growing demand for lower gastrointestinal diagnostics, marking a forecasted increase to 0.45 USD Billion by 2035, fueled by improving healthcare access.

South America holds a smaller market share at 0.1 USD Billion for 2024, anticipated to rise modestly to 0.15 USD Billion by 2035, largely due to emerging healthcare systems. Meanwhile, the MEA region, starting at 0.1 USD Billion in 2024 and expected to ascend to 0.25 USD Billion by 2035, shows potential growth through increasing healthcare investments and an expanding patient demographic. The segmentation underlines the global scope and competitive landscape within the Global Lower GI Series Market, emphasizing the disparities in market growth and the strategic opportunities afforded by each regional market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Lower GI Series Market Key Players and Competitive Insights

The Global Lower GI Series Market is characterized by a dynamic competitive landscape driven by advancements in technology, increasing patient awareness, and a growing emphasis on diagnostic accuracy. As healthcare providers continue to enhance the quality of gastrointestinal diagnostics, leading players in the market are continuously innovating their product offerings to better cater to the needs of patients and healthcare professionals alike. 

This market is integral to the accurate diagnosis of lower gastrointestinal tract conditions, where competition is not solely based on product offerings but also on service quality, customer relationships, and brand reputation. As the demand for non-invasive diagnostic procedures continues to rise, companies operating in this sector are adapting their strategies to ensure they remain at the forefront of technological advancements while navigating regulatory challenges effectively.

Pfizer stands as a strong player in the Global Lower GI Series Market, leveraging its deep-rooted expertise in the pharmaceutical sector to offer a robust portfolio aimed at enhancing diagnostic procedures for gastrointestinal conditions. The company has cultivated a strong market presence by focusing on innovative solutions that are both effective and accessible, aiming to improve patient outcomes through precise diagnostics. 

By continuously investing in research and development, Pfizer has strengthened its position as a reliable provider in this market, distinguishing itself through high-quality standards and effective patient support methodologies. Furthermore, Pfizer's strategic partnerships and collaborations with healthcare institutions and diagnostic centers enhance its visibility and service offerings within the global landscape.

Hologic excels in the Global Lower GI Series Market by providing specialized technology and equipment designed for lower gastrointestinal diagnostics. The company's key products and services are tailored to meet the demands of clinicians and patients, facilitating swift and accurate diagnoses. Hologic's commitment to innovation is evidenced by the development of imaging and diagnostic solutions that embody their expertise in women's health and gastrointestinal health. 

With a solid market presence, Hologic leverages its strengths in technological advancement and dedicated customer service. Additionally, mergers and acquisitions have played a significant role in expanding Hologic's market reach and enhancing its product capabilities, positioning the company to respond adeptly to evolving trends and needs in the global healthcare arena. By maintaining a focus on core competencies and exploring new market opportunities, Hologic continues to solidify its influence within the Global Lower GI Series Market.

Key Companies in the Lower GI Series Market Include

• Pfizer


• Hologic


• Abbott Laboratories


• Thermo Fisher Scientific


• Roche


• Johnson and  Johnson


• Boehringer Ingelheim


• Stryker


• Cleveland Clinic


• Novartis


• Medtronic


• BristolMyers Squibb


• GlaxoSmithKline


• Boston Scientific


• Siemens Healthineers

Lower GI Series Market Industry Developments

The Global Lower GI Series Market has witnessed significant activity in recent months, particularly with advancements from major players such as Pfizer, Hologic, Abbott Laboratories, and Thermo Fisher Scientific. Noteworthy developments include increased investments in Research and Development to enhance diagnostic capabilities and improve patient outcomes. 

In September 2023, Roche announced the expansion of its diagnostics portfolio aimed at lower gastrointestinal diseases, emphasizing precision medicine. Companies like Johnson and Johnson and Boehringer Ingelheim are focusing on innovative therapeutic options that have contributed to market growth, showcasing an increasing market valuation driven by rising demand for effective gastrointestinal diagnostics and treatment solutions. In terms of mergers and acquisitions, a notable transaction occurred in October 2023 when Stryker acquired a small company specializing in advanced imaging technologies for GI applications, enhancing its technological capabilities in the market. 

Other firms, such as Novartis and Medtronic, are similarly pursuing strategic partnerships to bolster their presence in this sector. The ongoing trends indicate a robust competitive landscape fueled by growing patient awareness and healthcare investments globally.

Lower GI Series Market Segmentation Insights

• 
  

  Lower GI Series Market Procedure Type Outlook

  
  
  
  
  • Barium Enema
  
  
  • Colonoscopy
  
  
  • CT Colonography
  
  
  • Fluoroscopy
  
  
  
  


• 
  

  Lower GI Series Market Application Outlook

  
  
  
  
  • Diagnostic Imaging
  
  
  • Routine Screening
  
  
  • Disease Monitoring
  
  
  • Therapeutic Intervention
  
  
  
  


• 
  

  Lower GI Series Market End User Outlook

  
  
  
  
  • Hospitals
  
  
  • Diagnostic Laboratories
  
  
  • Outpatient Clinics
  
  
  • Research Institutions
  
  
  
  


• 
  

  Lower GI Series Market Product Type Outlook

  
  
  
  
  • Contrast Media
  
  
  • Imaging Equipment
  
  
  • Consumables
  
  
  • Accessories
  
  
  
  


• 
  

  Lower GI Series Market Regional Outlook

  
  
  
  
  • North America
  
  
  • Europe
  
  
  • South America
  
  
  • Asia Pacific
  
  
  • Middle East and Africa
  
  
  
  

Report Attribute/Metric	Details
Market Size 2023	1.75(USD Billion)
Market Size 2024	1.82(USD Billion)
Market Size 2035	2.8(USD Billion)
Compound Annual Growth Rate (CAGR)	3.98% (2025 - 2035)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Pfizer, Hologic, Abbott Laboratories, Thermo Fisher Scientific, Roche, Johnson  and  Johnson, Boehringer Ingelheim, Stryker, Cleveland Clinic, Novartis, Medtronic, BristolMyers Squibb, GlaxoSmithKline, Boston Scientific, Siemens Healthineers
Segments Covered	Procedure Type, Application, End User, Product Type, Regional
Key Market Opportunities	Increased prevalence of gastrointestinal disorders, Growing demand for preventative diagnostic procedures, Advancements in imaging technology, Rising awareness about early diagnosis, Expanding healthcare infrastructure in emerging markets
Key Market Dynamics	Increasing prevalence of gastrointestinal disorders, Technological advancements in imaging techniques, Rising demand for minimally invasive procedures, Growing awareness of early diagnosis, Expanding healthcare infrastructure in emerging markets
Countries Covered	North America, Europe, APAC, South America, MEA